Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) – Stock analysts at Wedbush boosted their Q2 2023 earnings per share (EPS) estimates for Magenta Therapeutics in a research report issued on Tuesday, May 16th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their […]
Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 1,060,000 shares, a drop of 10.9% from the March 31st total of 1,190,000 shares. Currently, 2.4% of the company’s shares are short sold. Based […]